Navigation Links
Genomma Lab International Announces Second Quarter 2009 Results
Date:7/23/2009

MEXICO CITY, July 23 /PRNewswire/ -- Genomma Lab International, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended June 30, 2009. All figures included herein were prepared in accordance with Mexican GAAP; figures are stated in nominal Mexican pesos. Also, the following consolidated figures show the Company's Spanish operations reclassified as discontinued operations according to Mexican GAAP.

2Q09 Highlights (vs. 2Q08)

  • Net Sales reached Ps. 985.5 million, an increase of 50.7%.
  • Gross Profit was Ps. 724.8 million, an increase of 46.1%.
  • EBITDA(1) reached Ps. 256.9 million, an increase of 36.5%.
  • Consolidated Net Income of Ps. 122.9 million, an increase of 3.3%.
  • Earnings per Share(2) increased 16.8% to Ps. 1.03.
  • International Net Sales rose to Ps. 130.1 million, an increase of 220.9%.
  • During the second quarter, Genomma Lab successfully launched three products under three existing brands (Base Brands(3) and Prior Year Launches(4)) as part of the line extension strategy.
  • The Company also launched, during the second quarter, six products under six New Brands(5) as part of its new product launch plan.
  • As of June 30, 2009 the Company had a net cash position of Ps. 1,214.4 million.
  • During the second quarter of 2009, the Company acquired the brand of lotions Flor de Naranja Sanborns(MR), the brand of creams Teatrical, the brand of hair coloring Henna Egipcia, and a 99 year license for the use of Sanborns(MR) brands for the acquired brands.
  • Additionally, during the second quarter, the Company acquired the Jockey Club brand of men's personal care products. All of these brands are well-recognized brands in their respective markets and have been very popular among Mexican consumers for several decades.

(1) EBITDA is calculated by adding pre-operative expenses, depreciation and amortization to the operating income.

(2) Earnings per share are for the last 12 months and were calculated using the weighted average number of shares outstanding for the period.

(3) As defined later in the document.

(4) As defined later in the document.

(5) As defined later in the document.

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman of the Board and Chief Executive Officer, stated: "We are pleased to report our second quarter 2009 results, which showed a sound growth. We are currently experiencing a challenging economic environment, which has made difficult the Global Economy's performance; therefore, we will continue to proceed with caution. We were, once again, pleasantly surprised by the net sales level registered during this quarter; which proves that both the Company's business model, as well as its advertising strategies, continue to be successful. We expect to continue in this manner so as to continue gaining market share, increasing net sales and profitability, and thus, creating value for our shareholders.

During the second quarter of 2009, we acquired several brands, some of them are expected to strengthen our presence in certain categories, whereas others will allow us to enter new categories. We continue analyzing new initiatives, and remain committed to the growth-by-acquisitions strategy established in our Initial Public Offering. We believe that adverse economic conditions can contribute to finding attractive expansion opportunities for the Company."

For the complete version of this earnings report, please visit: www.genommalab.com

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model, the Company had net sales of Ps. 2,629.4 million and EBITDA of Ps. 691.1 million in 2008.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B"

(Bloomberg: labb.mx).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. Announces Second Quarter 2009 Results Conference Call
2. Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns
3. Genomma Lab Internacional Announces First Quarter 2009 Results
4. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
5. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
6. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
7. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
8. Genomma Lab, New Participant in Market-Maker Program
9. Genomma Lab Announces Initiation of Stock Repurchase Fund
10. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
11. Genomma Lab Announces 2009 Earnings Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology: